Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
05 November 2025 | Story Martinette Brits | Photo Supplied
Opus Cactus
Prof Maryna Boshoff from the Department of Sustainable Food Systems and Development, Lerato Mamabolo (UFS graduate, now employed at OPUS Cactus), and Sotirios Pilafidis, Head of Research and Development at OPUS Cactus, at the XI International Congress on Cacti as Food, Fodder and Other Uses, hosted by the FAO-ICARDA CactusNet in Tenerife, Canary Islands.

The University of the Free State (UFS) has formalised a collaboration with OPUS Cactus, a pioneering biotech company focused on sustainable cactus-based farming and biorefineries in semi-arid regions. This partnership builds on OPUS Cactus’ expansion at the historic Waterkloof Research Station near Bloemfontein and combines the UFS’ academic expertise with industry innovation to promote climate-smart agriculture and economic development.

OPUS Cactus, led by Joeri van den Bovenkamp-Hofman, CEO, and Sotirios Pilafidis, Head of Research and Development (R&D), specialises in transforming marginal, non-arable land into productive, resource-efficient ecosystems by cultivating the drought-tolerant Opuntia cactus. This versatile biomass supports renewable bioenergy, animal feed, food production, fermentation feedstock, and sustainable biomaterials, while contributing to carbon capture and climate mitigation efforts.

“Our mission is to unlock the full potential of Opuntia biomass for sustainable bioenergy, food, and biomaterials, advancing regenerative agriculture and climate action,” says Van den Bovenkamp-Hofman. OPUS Cactus operates dual hubs: its headquarters and R&D lab in Groningen, the Netherlands, and the flagship 1 000-hectare Waterkloof Research Centre in the Free State. The Waterkloof facility serves as a commercial farm, research platform, and demonstration site for regenerative farming techniques.

The UFS collaboration involves multiple departments, including Sustainable Food Systems and Development, Soil, Crop and Climate Sciences, and Microbiology and Biochemistry. Profs Maryna Boshoff and Carlien Pohl-Albertyn, alongside Dr Gesine Coetzer, provide academic leadership in the partnership.

Prof Boshoff explains, “This industry-academia collaboration aims to develop innovative projects utilising cactus-based products. It builds on decades of cactus research at the UFS, enabling the translation of scientific knowledge into real-world impact through scale-up and commercialisation.”

 

Bridging academic research and commercial innovation to promote climate-smart agriculture

At the core of the partnership is the Waterkloof Research Centre, home to 42 spineless Burbank cactus pear cultivars. The facility acts as a ‘living laboratory’, integrating empirical research with commercial-scale farming. “Waterkloof now offers students and researchers access to operational infrastructure that cannot be replicated in conventional academic settings,” says Prof Boshoff.

Continuing projects at Waterkloof include biogas production through an anaerobic digester, regenerative agriculture practices such as cover cropping and reduced tillage, advanced plant biotechnology to breed superior cultivars, fermentation research for alternative proteins, and the development of novel fermented foods and sustainable biomaterials.

The collaboration also plays a critical role in conserving Opuntia genetic diversity and evaluating cultivars across South Africa’s varied agro-ecological zones. “Research done by UFS and ARC scientists on cultivar selection and cultivation is applied and scaled up through OPUS Cactus’ commercial operations,” Prof Boshoff adds.

This partnership provides valuable hands-on experience and career pathways for postgraduate students and young researchers. “We offer internships and employment opportunities, with several recent UFS graduates already joining our R&D team,” says Pilafidis. “We actively seek motivated graduates passionate about sustainable agriculture and bioengineering.”

By converting semi-arid landscapes into productive, carbon-sequestering ecosystems, the UFS-OPUS Cactus collaboration exemplifies how scientific innovation, entrepreneurship, and environmental stewardship can drive climate resilience, food security, and sustainable economic growth.

“OPUS Cactus is a win for the environment, communities, and business alike,” concludes Van den Bovenkamp-Hofman.

News Archive

Nuclear Medicine on the forefront of cancer research
2017-07-10

Description: Nuclear Medicine on the forefront of cancer research Tags: Nuclear Medicine, cancer research, Dr Je’nine Horn-Lodewyk’s, tumour detection method, cancer, Department of Nuclear Medicine 

Dr Je’nine Horn-Lodewyk’s tumour detection method
could be the cost-effective breakthrough needed to decrease
the mortality rate in breast cancer patients.
Photo: Anja Aucamp

The field of Nuclear Medicine in South Africa and the rest of the world are expanding rapidly due to the development of hybrid cameras and new radiopharmaceuticals. These developments have a huge impact on the diagnosis and therapy of cancer.

The most advanced of these cameras, Positron emission tomography combined with normal CTs (PETCT), are not yet widely available in South Africa due to the cost of the cameras and the radiopharmaceuticals. A more cost-effective alternative can be of great benefit. To achieve this, the focus should be on developing new radiopharmaceuticals that can be used with the current cost-effective gamma cameras, according to University of the Free State researcher, Dr Je’nine Horn-Lodewyk from the Department of Nuclear Medicine.

Fluorodeoxyglucose (18F-FDG), a radiolabelled glucose analogue, is currently the radiopharmaceutical most commonly used in PET/CT imaging for mainly oncology indications. Although it is considered the gold standard for imaging in several malignancies, it does have certain disadvantages. An 18F-FDG PET/CT diagnostic imaging study can cost between R25 000 and R35 000 for a single patient in the private sector. The 18F-FDG is also more radioactive, which requires much stricter handling and shielding to avoid high radiation dosages to staff and patients.

Successful research potential innovative solution
In the search for the ideal radiopharmaceutical for tumour detection, the South African National Nuclear Energy Corporation (Necsa) developed a local synthesis process for ethylenedicysteine-deoxyglucose (EC-DG). EC-DG is also a glucose analogue similar to FDG. They succeeded in labelling the compound with Technetium-99-metastable-pertechnetate (99mTcO4-), the most common nuclear medicine isotope used for approximately 95% of nuclear medicine procedures, creating 99mTc-EC-DG.

In partnership with Dr Horn-Lodewyk, this compound was successfully used in various animal models and clinical scenarios, resulting in approval by the Medicine Control Council to use it in a human study. Research is also planned in order to investigate diagnostic accuracy in other cancers like lymphoma.  The end result of this research can produce a radiopharmaceutical that is cost effective, does not require the use of costly specialised equipment, has no significant side-effects, no special patient preparation, renders late imaging possible, and has decreased radiation risks.

Dr Horn-Lodewyk is grateful for the support of her mentor, Prof Anton Otto, as well as Dr Gert Engelbrecht, Head of the Department of Nuclear Medicine, Prof Jan Rijn Zeevaart from North-West University’s Preclinical Drug Development Platform and Necsa, and Judith Wagener from Necsa. This innovative research would also not have been possible without the financial assistance of Dr Glen Taylor and Eleanor van der Westhuizen in the Directorate of Research Development.

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept